Immunomedics, inc. (IMMU)
Income statement / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12Dec'11Sep'11Jun'11Mar'11Dec'10Sep'10
Revenues:
Total revenues

295

295

0

0

386

868

1,465

2,155

2,410

3,252

3,039

3,091

3,381

2,956

3,243

3,233

4,696

4,980

5,311

5,653

4,444

4,416

4,615

9,041

9,216

9,798

9,408

4,961

4,563

3,797

32,640

32,733

42,885

43,012

14,360

14,709

0

0

0

Costs and Expenses:
Costs of goods sold

-

-

0

0

-

47

543

613

659

747

297

483

1,135

1,338

1,355

1,159

507

242

246

264

286

303

337

338

381

384

373

392

388

385

427

427

425

433

406

419

0

0

0

Costs of license fee and other revenues

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,189

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Research and development

259,127

254,871

235,701

204,982

179,662

150,333

120,180

99,283

83,691

67,339

54,592

51,776

52,783

53,591

55,104

53,492

52,067

49,153

45,257

41,735

40,923

38,679

35,558

33,680

29,947

29,919

29,101

28,381

27,468

26,246

26,237

24,255

24,011

24,157

23,503

24,536

0

0

0

Sales and marketing

26,645

26,459

34,195

34,061

30,754

25,239

12,393

6,820

3,951

1,887

883

873

951

897

1,099

1,027

858

895

683

768

935

893

1,143

1,132

1,099

1,077

840

826

813

786

838

846

891

921

857

828

0

0

0

General and administrative

41,681

43,803

51,057

52,308

66,548

59,807

44,966

36,485

29,485

33,145

33,067

29,109

15,571

6,638

5,530

6,563

6,824

6,807

7,008

9,102

9,545

10,181

10,367

8,281

7,642

6,942

6,614

6,154

5,991

5,890

5,867

5,762

6,092

6,442

6,226

7,116

0

0

0

Total costs and expenses

327,453

325,133

320,953

291,351

276,964

235,426

178,084

143,203

117,787

103,121

88,840

82,241

70,443

62,465

63,090

62,241

60,257

57,099

53,195

51,872

51,690

50,058

47,406

44,621

40,259

39,513

38,118

35,754

34,662

33,308

33,371

31,291

31,421

31,954

30,993

32,900

0

0

0

Operating loss

-327,158

-324,838

-320,953

-291,351

-276,578

-234,558

-176,619

-141,048

-115,376

-99,868

-85,801

-79,150

-67,061

-59,508

-59,846

-59,008

-55,560

-52,119

-47,883

-46,219

-47,246

-45,642

-42,791

-35,580

-31,043

-29,714

-28,709

-30,792

-30,099

-29,511

-730

1,442

11,464

11,058

-16,633

-18,190

0

0

0

Fair Value Adjustment of Warrants

-

-

-204

-1,404

-

47,661

21,096

108,674

78,111

95,176

0

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Warrant related expenses

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Interest expense

43,916

40,337

40,206

40,601

39,410

40,351

30,749

23,254

15,191

5,661

6,757

5,480

5,480

5,480

5,480

5,480

4,830

0

0

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Arbitration settlement, net

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

Insurance proceeds received

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

Qualifying Therapeutic Discovery Project Program

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

Gain on auction rate securities, net

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

Interest and other income

8,080

7,856

10,650

10,149

11,874

10,801

6,771

5,493

2,139

1,074

761

431

299

317

331

338

434

385

312

245

85

67

74

55

-92

-105

-122

10

144

131

150

18

-268

-236

-4

239

0

0

0

Loss on induced exchanges of debt

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other financing expenses

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Insurance reimbursement

-

-

0

190

-

2,462

2,462

6,638

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Foreign currency transaction gain, net

-

-

0

0

-

-26

-2

81

323

339

104

23

-115

-245

-27

-40

-72

-4

0

-1

37

-16

-16

0

-22

17

-61

-37

-28

60

20

13

21

-33

19

26

0

0

0

Loss before income tax

-362,994

-357,319

-351,220

-321,106

-362,037

-310,191

-219,178

-273,731

-210,095

-233,858

-255,779

-153,246

-115,920

-72,493

-65,022

-64,190

-60,678

-56,569

-51,031

-48,065

-47,844

-45,591

-42,732

-35,523

-31,019

-12,926

-9,516

-11,442

-10,743

-26,819

-559

1,474

11,536

11,521

-12,996

-14,302

0

0

0

Income tax expense

0

0

0

0

156

156

0

0

0

-

0

-

-

-

-

-5,054

-5,040

-3,165

65

58

48

46

15

7

25

4

28

44

9

-187

215

209

210

501

76

109

0

0

0

Net Income (Loss), Including Portion Attributable to Noncontrolling Interest

-362,994

-357,319

-351,220

-321,106

-362,193

-310,347

-219,334

-273,887

-210,115

-233,878

-255,799

-153,266

-115,923

-70,624

-59,948

-59,136

-55,637

-53,404

-51,097

-48,123

-47,892

-45,638

-42,747

-35,531

-31,045

-12,930

-9,545

-11,486

-10,752

-26,631

-775

1,264

11,325

11,020

-13,073

-14,412

0

0

0

Net loss attributable to noncontrolling interest

-94

-129

-139

-148

-159

-104

-76

-53

-56

-58

-45

-60

-70

-82

-107

-99

-101

-107

-111

-121

-121

-117

-112

-105

-106

-105

-104

-104

-106

-110

-113

-113

-230

0

0

-

0

-

-

Net loss attributable to Immunomedics, Inc. stockholders

-362,900

-357,190

-351,081

-320,958

-362,034

-310,243

-219,257

-273,833

-210,059

-233,819

-255,753

-153,206

-115,852

-70,542

-59,841

-59,037

-55,536

-53,296

-50,985

-48,002

-47,771

-45,520

-42,635

-35,425

-30,939

-12,825

-9,441

-11,381

-10,646

-26,521

-661

1,378

11,438

11,247

-12,873

-14,238

0

0

0

Loss per common share attributable to Immunomedics, Inc. stockholders:
Loss per common share attributable to Immunomedics, Inc. stockholders (basic and diluted) (in usd per share)

-0.44

-0.49

-0.49

-0.40

-0.46

-0.50

-0.34

-0.68

-0.21

-0.02

-0.97

-0.52

-0.55

-0.23

-0.17

-0.16

-0.15

-0.15

-0.16

-0.13

-0.13

-0.12

-0.13

-0.15

-0.11

-0.10

-0.06

-

-

-0.07

-0.09

-

-

-

-0.07

-

-

-

-0.09

Basic

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0.11

-

-

-

-0.10

0.27

-

-

-0.10

-0.05

-

Diluted

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0.11

-

-

-

-0.10

0.27

-

-

-0.10

-0.05

-

Weighted average shares used to calculate loss per common share:
Weighted average shares used to calculated loss per common share (basic and diluted) (in shares)

213,247

199,690

191,981

191,745

191,052

190,171

186,937

171,124

166,054

154,486

122,550

109,763

107,839

104,657

95,883

95,071

94,748

94,664

94,595

93,652

93,351

93,157

93,098

89,063

83,340

83,174

82,947

-

-

75,671

75,610

-

-

-

75,435

-

-

-

-

Basic

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

78,195

-

-

-

75,490

75,458

-

-

75,317

75,289

-

Diluted

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

78,447

-

-

-

75,490

75,964

-

-

75,317

75,289

-

Other comprehensive loss, net of tax:
Foreign currency translation adjustments

174

174

129

178

33

-24

-27

-104

-275

-261

-172

-62

24

149

20

1

112

-214

-239

-434

-534

-277

-150

100

169

99

93

81

-80

46

-75

-314

-224

-114

-66

262

0

0

0

Consolidated net (loss) income

-362,994

-357,319

-351,220

-321,106

-362,193

-310,347

-219,334

-273,887

-210,115

-233,878

-255,799

-153,266

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

Unrealized loss on securities available for sale

-416

-391

-396

-190

-136

74

37

54

-56

-60

-44

-109

-36

49

-38

28

17

-57

49

11

-5

-25

0

-0

0

0

0

-

-

-

-

-

-

-

-

-208

0

0

0

Other Comprehensive Income (Loss), Net of Tax

-242

-217

-267

-12

-103

50

9

-50

-331

-322

-216

-171

-12

198

-17

29

129

-271

-189

-422

-539

-303

-149

100

180

114

88

81

-80

46

-75

-314

-224

-528

-398

53

0

0

0

Net comprehensive (loss) income

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

-

0

0

-

-

-

-

Comprehensive loss

-363,236

-357,536

-351,487

-321,118

-362,296

-310,297

-219,324

-273,937

-210,447

-234,200

-256,015

-153,437

-115,935

-70,425

-59,966

-59,107

-55,507

-53,675

-51,286

-48,546

-48,432

-45,941

-42,897

-35,431

0

0

0

-

-

110

113

113

-15,032

0

0

-

0

-

-

Comprehensive loss attributable to noncontrolling interest

-94

-129

-139

-148

-159

-104

-76

-53

-56

-58

-45

-60

-70

-82

-107

-99

-101

-107

-111

-121

-121

-117

-112

-105

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Comprehensive loss attributable to Immunomedics, Inc. stockholders

-363,142

-357,407

-351,348

-320,970

-362,137

-310,193

-219,247

-273,883

-210,390

-234,141

-255,969

-153,377

-115,864

-70,343

-59,858

-59,008

-55,406

-53,567

-51,174

-48,425

-48,310

-45,823

-42,785

-35,325

-30,759

-12,710

-9,352

-11,299

-10,727

-26,475

-737

1,063

11,213

10,718

-13,272

-14,184

0

0

0

Product sales
Revenues

-

-

0

0

-

450

973

1,499

2,106

2,578

2,371

2,443

2,382

2,004

2,277

2,261

2,179

2,330

2,502

2,648

2,890

3,120

3,309

3,140

3,206

3,032

2,816

2,991

3,043

3,060

3,391

3,517

3,592

3,672

3,337

3,607

0

0

0

License fee and other revenues
Revenues

-

-

0

0

-

265

328

329

81

323

269

284

367

375

391

387

552

0

0

-

0

-

-

4,623

4,750

0

0

-

0

-

-

-

-

0

-

-

0

0

-

Research and development
Revenues

-

-

0

0

-

153

162

325

222

350

397

364

631

576

575

585

1,214

1,363

1,548

1,754

1,304

1,295

1,306

1,277

1,386

2,015

1,841

1,844

1,392

736

831

798

838

869

896

975

0

0

0